The antitrust regulator in Spain has accused Merck of working with other companies to hinder the entry of generic versions of a hormonal contraceptive, the latest effort by a European government to crack down on anti-competitive practices in the pharmaceutical industry.
In a statement issued the National Commission on Markets and Competition announced that it is pursuing sanctions against Merck Sharp & Dohme, its European affiliate, and MSD Human Health Holding, the European parent, for possibly delaying competitors from entering the market for a vaginal ring in Spain.
Full Content: Stat News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.